Table 1 Baseline characteristics of study population.
Total | Non-OCAD | OCAD | p | |
|---|---|---|---|---|
(N = 1741) | (N = 1080) | (N = 661) | ||
Age, mean (SD) | 61.4 (11.3) | 59.1 (11.3) | 65.3 (10.3) | < 0.001 |
Men, n (%) | 586 (33.7) | 336 (31.1) | 250 (37.8) | 0.004 |
Chest pain, n (%) | < 0.001 | |||
Non-specific | 248 (14.2) | 182 (16.9) | 66 (10.0) | |
Atypical | 640 (36.8) | 417 (38.6) | 223 (33.7) | |
Typical | 853 (49.0) | 481 (44.5) | 372 (56.3) | |
Obesity, n (%) | 818 (47.0) | 502 (46.4) | 316 (47.8) | 0.361 |
BMI, mean (SD) | 25.0 (3.5) | 25.0 (3.5) | 24.9 (3.5) | 0.573 |
Hypertension, n (%) | 909 (52.2) | 501 (46.4) | 408 (61.7) | < 0.001 |
DM, n (%) | 366 (21.0) | 166 (15.4) | 200 (30.3) | < 0.001 |
Dyslipidemia, n (%) | 345 (19.8) | 206 (19.1) | 139 (21.0) | 0.321 |
Family history of CAD, n (%) | 303 (17.4) | 180 (16.7) | 123 (18.6) | 0.166 |
Current smoker, n (%) | 240 (13.8) | 123 (11.4) | 117 (17.7) | < 0.001 |
Antidiabetic drug therapy, n (%) | 296 (17.0) | 132 (12.2) | 164 (24.8) | < 0.001 |
Antihyperlipidemic drug therapy, n (%) | 759 (43.6) | 421 (39.0) | 338 (51.1) | < 0.001 |
Antithrombotic drug use | ||||
Aspirin, n (%) | 694 (39.9) | 369 (34.2) | 325 (49.2) | < 0.001 |
Clopidogrel, n (%) | 418 (24.0) | 196 (18.1) | 222 (33.6) | < 0.001 |
Antihypertensive drug therapy | ||||
RAS inhibitor, n (%) | 549 (31.5) | 282 (26.1) | 267 (40.4) | < 0.001 |
CCB, n (%) | 482 (27.7) | 312 (28.9) | 170 (25.7) | 0.084 |
β-blockers, n (%) | 385 (22.1) | 171 (15.8) | 214 (32.4) | < 0.001 |
Diuretics, n (%) | 121 (7.0) | 56 (5.2) | 65 (9.8) | < 0.001 |
Electrocardiography | ||||
QTc interval (ms) | 434.5 (31.3) | 429.0 (27.8) | 443.5 (34.4) | < 0.001 |
Heart rate (/min) | 70.0 (12.6) | 69.1 (91.8) | 71.4 (13.8) | < 0.001 |
QRS duration (ms) | 91.3 (28.2) | 91.4 (32.6) | 91.3 (19.3) | 0.932 |
